Clinical trials: Advanced Soft Tissue Sarcoma
Sarcoma
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
The overall goal of this Phase 2 study is to determine the efficacy of a lower dose weekly schedule of doxorubicin in patients with unresectable leiomyosarcomas aged 65-100 years old.
- Trial name
- NCT07125183
- Testing
- Doxorubicin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rhabdomyosarcoma
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
This phase I trial studies the side effects and best dose of mocetinostat when given together with vinorelbine to see how well it works in treating children, adolescents, and young adults with rhabdomyosarcoma that has spread to…
- Trial name
- NCT04299113
- Testing
- Vinorelbine, Mocetinostat
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
Lung Cancer, Malignant Mesothelioma
Alanosine in Treating Patients With Cancer
RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
- Trial name
- NCT00062283
- Testing
- L-alanosine
- Where
- 12 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
This phase I trial tests the safety, side effects, and best dose of combination therapy with pelcitoclax (APG-1252) and cobimetinib in treating patients with ovarian and endometrial cancers that have come back after a period of…
- Conditions
- Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Platinum-Resistant Ovarian Carcinoma
- Trial name
- NCT05691504
- Testing
- Biopsy Procedure, Biospecimen Collection, Cobimetinib
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT00937495
- Testing
- vorinostat, bortezomib
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Soft Tissue Sarcoma, Renal Cell Carcinoma
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study.
- Conditions
- Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma
- Trial name
- NCT05229601
- Testing
- HFB301001
- Where
- 10 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- HiFiBiO Therapeutics
Sarcoma, Soft Tissue Sarcoma
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT04906876
- Testing
- Gemcitabine, Docetaxel, 9-ING-41
- Where
- 2 sites in United States
- Sponsor
- Brown University
Sarcoma, Castrate Resistant Prostate Cancer
A Study of PRT2527 in Participants With Advanced Solid Tumors
This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors.
- Conditions
- Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05159518
- Testing
- PRT2527
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Prelude Therapeutics Incorporated
Neoplasms
Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
To assess the safety, tolerability and determine recommended phase 2 dose (RP2D) of GSK3845097 in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 positive participants with New York esophageal squamous cell carcinoma (NY-ESO)-1…
- Trial name
- NCT05943990
- Testing
- GSK3845097, Cyclophosphamide, Fludarabine
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 5 people
- Sponsor
- Adaptimmune
Angiosarcoma
Evaluation of Votrient in Angiosarcoma
Open-label phase II trial investigating the efficacy and safety of the investigational combination of pazopanib and paclitaxel.
- Trial name
- EVA (NCT02212015)
- Testing
- Pazopanib + Paclitaxel
- Where
- 10 sites in Austria, Germany
- Volunteers
- 26 people
- Sponsor
- Heidelberg University
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.